Physician

Internal Medicine

Dr. Danelle F. James works in the field of Internal Medicine. She went to Penn State College of Medicine. Danelle James has written publications. She has 17 publications published with PubMed. The lastest paper is: 'The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, with chemoimmunotherapy in patients with chronic lymphocytic leukemia.'

Publications

---

• Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib.
• The Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, with chemoimmunotherapy in patients with chronic lymphocytic leukemia.
• Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
• The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia.
• Modeling absolute lymphocyte counts after treatment of chronic lymphocytic leukemia with ibrutinib.
• Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.
• Lenalidomide and Rituximab for the Initial Treatment of Patients With Chronic Lymphocytic Leukemia: A Multicenter Clinical-Translational Study From the Chronic Lymphoc...
• Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia.
• Kinetics of chronic lymphocytic leukemia (CLL) cells in tissues and blood during therapy with the BTK inhibitor ibrutinib.
• Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.
• Rituximab in chronic lymphocytic leukemia.
• B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia.
• BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway.
• Ofatumumab and high-dose methylprednisolone for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia.
• Analysis of CLLU1 expression levels before and after therapy in patients with chronic lymphocytic leukemia.
• Alemtuzumab in chronic lymphocytic leukemia.

Schools

---

• Pennsylvania State University College of Medicine

• University Ca

Doctors Specialties

---

• Hematology
• Internal Medicine

Accepted Insurances

---

Education

---

• University of California San Diego
• Penn State College of Medicine

Helpful Reviews

---

Give Anonymous Review

Similar Doctors

---

	Dr. Gaston R. Molina Jr., MD This Doctor is OpenDoctor Recommended.
	Dr. Heidi L. Fagerlund, DO
	Dr. Alexis S. Rahal, MD This Doctor is OpenDoctor Recommended.
	Dr. Taylor L. Barnett, MD
	Dr. Peter G. Phung, MD
	Dr. Victor A. Stewart, MD This Doctor is OpenDoctor Recommended.
	Dr. Marie P. Shieh, MD This Doctor is OpenDoctor Recommended.
	Dr. Joshua D. Rosenberg, MD This Doctor is OpenDoctor Recommended.
	Dr. Richard B. Schwab, MD This Doctor is OpenDoctor Recommended.
	Dr. Teresa L. Helsten, MD This Doctor is OpenDoctor Recommended.
	Dr. Michael Quigley, MD This Doctor is OpenDoctor Recommended.
	Dr. Catriona Jamieson, MD This Doctor is OpenDoctor Recommended.
	Dr. Erin G. Reid, MD This Doctor is OpenDoctor Recommended.
	Sabina R. Wallach, MB This Doctor is OpenDoctor Recommended.

---

Doctor Directory | TOS | twitter | FB | Angel | blog